KURN Share Price Performance
Recent KURN News & Updates
No updates
Kuros Biosciences AG Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
Aug 14, 2025
- Earnings per share (EPS)
- -0.097
- Gross Margin
- 88.85%
- Net Profit Margin
- -4.92%
- Debt/Equity Ratio
- 0%
Kuros Biosciences AG Competitors
About KURN
- Founded
- 2016
- Employees
- 122
- CEO
- WebsiteView website
Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold uses to fill bony voids for intervertebral disc space or posterolateral spine; and Attrax, a biphasic calcium phosphate bone grafts that mimic the porous and trabecular structure of cancellous bone, as well as checkmate licensing. The company was incorporated in 2016 and is headquartered in Schlieren, Switzerland.
Swiss Market Performance
- 7 Days: -1.9%
- 3 Months: -1.9%
- 1 Year: -2.7%
- Year to Date: 2.2%
Over the last 7 days, the market has dropped 1.9%, driven by a decline of 1.9% in the Healthcare sector. Overall the market has been flat in the last year. Earnings are forecast to grow by 11% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading